Patent Prosecution in Proteomics
نویسندگان
چکیده
This paper presents a brief overview of intellectual property rights and the various areas in proteomics to which IP rights may be applicable. Technology transfer, including licensing and business agreements, are not covered in this paper. Instead, issues and complications related to national and overseas patent prosecution in this relatively new field will be discussed.
منابع مشابه
Patent prosecution strategies for stem cell related applications.
Stem cell research and the intellectual property derived from it, because of its potential to completely transform health care, demand an especially high level of consideration from business and patent prosecution perspectives. As with other revolutionary technologies, ordinary risks are amplified (e.g., litigation), and ordinarily irrelevant considerations may become important (e.g., heightene...
متن کاملRethinking Prosecution History Estoppel
Under the rule of prosecution history estoppel, patent applicants who amend their claims during the course of patent prosecution assume a significant risk: the risk that a court will later construe the changes as concessions that should be read to limit patent scope. This risk is exacerbated by strong evidentiary presumptions under which courts are to assume, unless the patentee presents suffic...
متن کاملOperation Restoration: How Can Patent Holders Protect Themselves from Medimmune?
The Supreme Court’s recent decision in MedImmune v. Genentech shifts the balance of power in license agreements from patent holders to their licensees. This iBrief outlines the potential implications of the new rules on all stages of patent prosecution and protection. Further, it evaluates remedial contract provisions patent holders may include in future license agreements and how these provisi...
متن کاملWays To Avoid Obviousness - Type Double Patenting
Law360, New York (May 13, 2016, 12:15 PM ET) -Obviousness-type double patenting (ODP) is a judicially created doctrine intended to prevent an improper timewise extension of patent rights by prohibiting the issuance to a single entity of claims in a second patent which are not "patentably distinct" from the claims of a first patent.[1] Claims are not patentably distinct from each other if one cl...
متن کاملTips For Avoiding Problematic Terminal Disclaimers
The Federal Circuit’s recent decisions in STC.UNM v. Intel Corp.[1] and In re Dinsmore[2] illustrate dangers associated with filing a terminal disclaimer to overcome a nonstatutory double-patenting rejection. In each case, the appellant tried to address the requirement that the terminally disclaimed patent had to be commonly owned with a patent owned by another party in order to be enforceable....
متن کامل